Quantcast

Latest Psoriasis Stories

2014-02-19 08:31:28

Proceeds Bring Series B to CHF 44.9 Million ZURICH-SCHLIEREN, Switzerland, Feb. 19, 2014 /PRNewswire/ -- Covagen today announced it has added Baxter Ventures as an investor in its Series B financing round raising the total to CHF 44.9 million. The Series B includes an option for all existing investors to invest an additional CHF 14 million in the future potentially increasing the total amount of this financing round to CHF 58.9 million. The additional financing will primarily...

2014-02-19 08:30:00

ALBANY, New York, February 19, 2014 /PRNewswire/ -- ResearchMoz.us includes new market research report "Hepatitis C Therapeutics in Major Developed Markets to 2019 [http://www.researchmoz.us/hepatitis-c-therapeutics-in-major-developed-markets-to-2019-outstanding-recent-approvals-and-late-stage-pipeline-to-transform-clinical-and-commercial-landscape-report.html ] " to its huge collection of research reports. Researchmoz presents this most up-to-date research on...

2014-02-18 08:30:20

PETACH TIKVA, Israel, Feb. 18, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the Company's development plan for 2014. Following a productive 2013, Can-Fite plans to continue its positive momentum in 2014 with further advancement of its drug portfolio, which it believes will translate into growth catalysts poised to drive...

2014-02-13 16:28:03

HORSHAM, Pa. and CINCINNATI, Feb. 13, 2014 /PRNewswire/ -- -- Combines a leading developer and marketer of skin health and wellness products to consumers and patients worldwide with a market-leading clinical service delivery platform utilizing direct-to-consumer customer acquisition model -- Expected to bring recurring, reimbursed revenue from the XTRAC(®) Excimer Laser for treating psoriasis and vitiligo and dispensing of the Neova(®)...

2014-02-06 23:25:01

ResearchMoz.us include new market research report "Cystic Fibrosis Therapeutics in Major Developed Markets to 2019" to its huge collection of research reports. Full Report @ http://www.researchmoz.us/cystic-fibrosis-therapeutics-in-major-developed-markets-to-2019-cftr-modulators-initiate-drive-towards-personalized-treatment-and-market-growth-report.html Albany, NewYork (PRWEB) February 06, 2014 GBI Research has released its pharma report “Cystic Fibrosis Therapeutics in Major...

2014-02-06 23:24:53

MarketResearchReports.Biz announces addition of new report “Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description” to its database. Visit: http://www.marketresearchreports.biz/analysis/186872 Albany, NY (PRWEB) February 06, 2014 Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description Research...

2014-01-31 23:34:52

Atlanta Dermatologist, Dr. Jamie Weisman, has opened her own dermatology practice in Atlanta, Georgia. Formerly with Peachtree Dermatology, Dr. Weisman now practices dermatology in her own medical practice, Medical Dermatology Specialists, Inc., located near Northside Hospital on Johnson Ferry Road. Atlanta, GA (PRWEB) January 31, 2014 Dr. Jamie D. Weisman, formerly of Peachtree Dermatology, is pleased to announce the opening of her new dermatology practice, Medical Dermatology...

2014-01-20 23:23:41

Psoriasis Cleanse designed by Sheri Green is the latest program that teaches people how to eliminate their unwanted itchy scales, plaques or inflamed skin. A full review on the site HealthReviewCenter.com indicates if Psoriasis Cleanse is worth buying. Seattle, Wa (PRWEB) January 20, 2014 Psoriasis or psoriasis vulgaris is a chronic inflammatory skin disease, which can also affect the joints. It is characterized by scaly and reddened patches, papules, and plaques that are usually itchy...

2014-01-16 16:24:09

AUSTIN, Texas, Jan. 16, 2014 /PRNewswire/ -- XBiotech announced today that it has launched a Phase II study to treat a rare but debilitating disorder, Pyoderma Gangrenosum (PG). This study is based on efficacy seen with anti-IL-1 therapeutic antibody in previous dermatological clinical studies such as psoriasis and acne. PG is expected to be considered an "orphan indication" by the FDA, facilitating expedited clinical development to market. Dr. Armand Cognetta, lead clinical...

2014-01-13 08:26:42

PETACH TIKVA, Israel, Jan. 13, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it will present new data based on a further analysis of results from its Phase IIb study of CF101 for the treatment of Rheumatoid Arthritis and interim data from its Phase II/III study of CF101 for the treatment of Psoriasis at the...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'